, GlobeNewswire
Addex to Host FY2009 Financial Results Conference Call on Feb. 23
Addex Pharmaceuticals / Addex to Host FY2009 Financial Results Conference Call on Feb. 23 verarbeitet und übermittelt durch Hugin. Für den Inhalt der Mitteilung ist der Emittent verantwortlich.
Geneva, Switzerland, 16 February 2010 - Addex Pharmaceuticals (SWX:ADXN), the
allosteric modulation company, will discuss its 2009 full year financial results
during a conference call and webcast for investors, analysts and the media on
Tuesday, 23 February 2010 at 16:00 CET. The financial results press release will
be issued prior to the start of trading on the SIX Swiss Exchange stock market
earlier the same day.
Addex Full Year 2009 Financial Results Conference Call:
Date: 23 February 2009
Time: 16:00 CET/15:00 GMT/10:00 EST
Dial-in numbers:
+41 91 610 56 00 (Europe)
+44 207 107 0611 (UK)
+1 866 291 4166 (USA)
Webcast & slides (replay and transcript) will be made available at
www.addexpharma.com
Addex Pharmaceuticals (www.addexpharma.com
utilizes its unique proprietary platform technologies to discover and develop
allosteric modulators for human health. Allosteric modulators are a different
kind of orally available small molecule therapeutic agent, which we believe will
offer a competitive advantage over classical drugs. With 15 programs in
development, the Addex pipeline demonstrates the productivity and broad
potential of our unparalleled platform technologies. The most advanced product,
ADX48621, an mGluR5 negative allosteric modulator (NAM), has completed Phase I
testing and is scheduled to start Phase II testing for Parkinson's disease
levodopa associated dyskinesia (PD-LID) later in 2010.
Our products and technology already have proven their value through our
relationships with four of the top 10 pharmaceutical companies in the world.
Specifically, under an agreement withOrtho-McNeil-Janssen Inc., a Johnson &
Johnson company, ADX71149, an mGluR2 positive allosteric modulator (PAM), is
undergoing Phase I clinical testing and has potential for treatment of
schizophrenia and anxiety. Under two separate agreements with Merck & Co., Inc.,
we are developing PAMs of mGluR4 and mGluR5 as drugs to treat Parkinson's
disease and schizophrenia, respectively. In addition, SR-One, the corporate
venture arm of GlaxoSmithKline, and Roche Venture Fund have made equity
investments in Addex.
Chris Maggos
Investor Relations & Communications
Addex Pharmaceuticals
+41 22 884 15 11
chris.maggos@addexpharma.com
Disclaimer: The foregoing release contains forward-looking statements that can
be identified by terminology such as "not approvable", "continue", "believes",
"believe", "will", "remained open to exploring", "would", "could", or similar
expressions, or by express or implied discussions regarding Addex
Pharmaceuticals Ltd, its business, the potential approval of its products by
regulatory authorities, or regarding potential future revenues from such
products. Such forward-looking statements reflect the current views of Addex
Pharmaceuticals Ltd regarding future events, and involve known and unknown
risks, uncertainties and other factors that may cause actual results with
allosteric modulators of mGluR4, mGluR2, mGluR5 or other therapeutic targets to
be materially different from any future results, performance or achievements
expressed or implied by such statements. There can be no guarantee that
allosteric modulators of mGluR4, mGluR2 or mGluR5 will be approved for sale in
any market or by any regulatory authority. Nor can there be any guarantee
that allosteric modulators of mGluR4, mGluR2, mGluR5 or other therapeutic
targets will achieve any particular levels of revenue (if any) in the future. In
particular, management's expectations regarding allosteric modulators of
mGluR4, mGluR2, mGluR5 or other therapeutic targets could be affected by, among
other things, unexpected actions by our partners, unexpected regulatory actions
or delays or government regulation generally; unexpected clinical trial results,
including unexpected new clinical data and unexpected additional analysis of
existing clinical data; competition in general; government, industry and general
public pricing pressures; the company's ability to obtain or maintain patent or
other proprietary intellectual property protection. Should one or more of these
risks or uncertainties materialize, or should underlying assumptions prove
incorrect, actual results may vary materially from those anticipated, believed,
estimated or expected. Addex Pharmaceuticals is providing the information in
this press release as of this date and does not undertake any obligation to
update any forward-looking statements contained in this press release as a
result of new information, future events or otherwise.
[HUG#1384989]
--- Ende der Mitteilung ---
Addex Pharmaceuticals
12, chemin des Aulx Plan-les-Ouates; Geneva Schweiz
ISIN: CH0029850754;
Geneva, Switzerland, 16 February 2010 - Addex Pharmaceuticals (SWX:ADXN), the
allosteric modulation company, will discuss its 2009 full year financial results
during a conference call and webcast for investors, analysts and the media on
Tuesday, 23 February 2010 at 16:00 CET. The financial results press release will
be issued prior to the start of trading on the SIX Swiss Exchange stock market
earlier the same day.
Addex Full Year 2009 Financial Results Conference Call:
Date: 23 February 2009
Time: 16:00 CET/15:00 GMT/10:00 EST
Dial-in numbers:
+41 91 610 56 00 (Europe)
+44 207 107 0611 (UK)
+1 866 291 4166 (USA)
Webcast & slides (replay and transcript) will be made available at
www.addexpharma.com
Addex Pharmaceuticals (www.addexpharma.com
utilizes its unique proprietary platform technologies to discover and develop
allosteric modulators for human health. Allosteric modulators are a different
kind of orally available small molecule therapeutic agent, which we believe will
offer a competitive advantage over classical drugs. With 15 programs in
development, the Addex pipeline demonstrates the productivity and broad
potential of our unparalleled platform technologies. The most advanced product,
ADX48621, an mGluR5 negative allosteric modulator (NAM), has completed Phase I
testing and is scheduled to start Phase II testing for Parkinson's disease
levodopa associated dyskinesia (PD-LID) later in 2010.
Our products and technology already have proven their value through our
relationships with four of the top 10 pharmaceutical companies in the world.
Specifically, under an agreement withOrtho-McNeil-Janssen Inc., a Johnson &
Johnson company, ADX71149, an mGluR2 positive allosteric modulator (PAM), is
undergoing Phase I clinical testing and has potential for treatment of
schizophrenia and anxiety. Under two separate agreements with Merck & Co., Inc.,
we are developing PAMs of mGluR4 and mGluR5 as drugs to treat Parkinson's
disease and schizophrenia, respectively. In addition, SR-One, the corporate
venture arm of GlaxoSmithKline, and Roche Venture Fund have made equity
investments in Addex.
Chris Maggos
Investor Relations & Communications
Addex Pharmaceuticals
+41 22 884 15 11
chris.maggos@addexpharma.com
Disclaimer: The foregoing release contains forward-looking statements that can
be identified by terminology such as "not approvable", "continue", "believes",
"believe", "will", "remained open to exploring", "would", "could", or similar
expressions, or by express or implied discussions regarding Addex
Pharmaceuticals Ltd, its business, the potential approval of its products by
regulatory authorities, or regarding potential future revenues from such
products. Such forward-looking statements reflect the current views of Addex
Pharmaceuticals Ltd regarding future events, and involve known and unknown
risks, uncertainties and other factors that may cause actual results with
allosteric modulators of mGluR4, mGluR2, mGluR5 or other therapeutic targets to
be materially different from any future results, performance or achievements
expressed or implied by such statements. There can be no guarantee that
allosteric modulators of mGluR4, mGluR2 or mGluR5 will be approved for sale in
any market or by any regulatory authority. Nor can there be any guarantee
that allosteric modulators of mGluR4, mGluR2, mGluR5 or other therapeutic
targets will achieve any particular levels of revenue (if any) in the future. In
particular, management's expectations regarding allosteric modulators of
mGluR4, mGluR2, mGluR5 or other therapeutic targets could be affected by, among
other things, unexpected actions by our partners, unexpected regulatory actions
or delays or government regulation generally; unexpected clinical trial results,
including unexpected new clinical data and unexpected additional analysis of
existing clinical data; competition in general; government, industry and general
public pricing pressures; the company's ability to obtain or maintain patent or
other proprietary intellectual property protection. Should one or more of these
risks or uncertainties materialize, or should underlying assumptions prove
incorrect, actual results may vary materially from those anticipated, believed,
estimated or expected. Addex Pharmaceuticals is providing the information in
this press release as of this date and does not undertake any obligation to
update any forward-looking statements contained in this press release as a
result of new information, future events or otherwise.
[HUG#1384989]
--- Ende der Mitteilung ---
Addex Pharmaceuticals
12, chemin des Aulx Plan-les-Ouates; Geneva Schweiz
ISIN: CH0029850754;
Relevante Links: Addex Therapeutics Ltd